<DOC>
	<DOCNO>NCT02016417</DOCNO>
	<brief_summary>The present study randomize , control , phase II study locally advance nasopharyngeal carcinoma ( NPC ) treat Gemcitabine plus cisplatin regimen ( GP ) Docetaxel，cisplatin regimen plus 5-Fluorouracil ( TPF ) induction chemotherapy follow concurrent chemoradiotherapy .</brief_summary>
	<brief_title>Induction Chemotherapy With GP Versus TPF Treatment Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Nasopharyngeal carcinoma ( NPC ) prevalence report high southern China , average 80 case per 100,000 population report year . Nasopharyngeal carcinoma radiosensitive chemosensitive . The National Comprehensive Cancer Network ( NCCN ) guideline ( version 1 , 2013 ) , recommend use concurrent chemoradiotherapy ( CCRT ) without adjuvant chemotherapy ( AC ) induction chemotherapy ( IC ) follow CCRT plus AC standard treatment NPC . However , unclear whether patient NPC could benefit IC . Recently , many new drug include docetaxel gemcitabine incorporate induction chemotherapy phase NPC . The investigator design present study induction chemotherapy follow CCRT locoregionally advance NPC , compare induction chemotherapy regime gemcitabine plus cisplatin ( GP ) docetaxel , cisplatin , fluorouracil ( TPF ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients newly histologically confirm nonkeratinizing ( accord WHO histologically type ) . 2 . 18 year 70 year ; 3 . Tumor stag T34N1/N23M0 ( accord 7th AJCC edition ) , 4 . Performance status : Karnofsky scale ( KPS ) &gt; 70 ( Appendix I ) . 5 . Adequate marrow : leucocyte count &gt; 4×109/L , neutrophil count &gt; 2×109/L , hemoglobin &gt; 90g/L platelet count &gt; 100×109/L . 6 . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) &lt; 2.5×ULN , bilirubin &lt; ULN . 7 . Adequate renal function : creatinine clearance &gt; 60 ml/min . 8 . Patients must inform investigational nature study give write informed consent . 1. WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . 2 . Age &gt; 70 &lt; 18 . 3 . Treatment palliative intent . 4 . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . 5 . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . 6 . History previous RT ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . 7 . Prior chemotherapy surgery ( except diagnostic ) primary tumor node . 8 . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Docetaxel</keyword>
</DOC>